As BTK plays a role in both BCR and TLR signaling, the therapeutic strategy of BTK inhibition is effective for patients with PCNSL as a phase I trial of ibrutinib monotherapy in PCNSL patients produced an overall response rate of 77% (n=10/13) including 5 complete responses (53). Here, BTK is linked to primary central nervous system lymphoma.